Protara Therapeutics (TARA) Total Current Liabilities (2013 - 2026)

Protara Therapeutics' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 27.13% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (up 27.13% YoY), while the FY2025 annual figure was $10.9 million, changed 0.2% from the prior year.
• Total Current Liabilities was $8.9 million for Q1 2026 at Protara Therapeutics, down from $10.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $11.0 million in Q4 2024 to a low of $2.9 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $6.9 million across 5 years, with a median of $6.4 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 124.05% in 2023, then dropped 14.18% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $5.7 million in 2022, then increased by 7.13% to $6.1 million in 2023, then surged by 78.26% to $11.0 million in 2024, then decreased by 0.2% to $10.9 million in 2025, then slipped by 18.44% to $8.9 million in 2026.
• The last three Total Current Liabilities figures came in at $8.9 million (Q1 2026), $10.9 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.